ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.928,94
-0,06%
S&P 500
5.741,85
-0,06%
US Dollar vs BRL
5,4365
-0,03%
Bitcoin
65.821,71
0,98%
Brent Oil
71,785
1,18%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Hepion Pharmaceuticals Inc (HEPA)

  7. Hepion Pharmaceuticals Inc (HEPA) Notícias

HEPA

Hepion Pharmaceuticals (HEPA)

Hepion Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:HEPA
DataHoraFonteTítuloCódigoCompanhia
04/09/202410:25GlobeNewswire Inc.Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed MergerNASDAQ:HEPAHepion Pharmaceuticals Inc
07/08/202410:08Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:HEPAHepion Pharmaceuticals Inc
07/08/202410:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HEPAHepion Pharmaceuticals Inc
22/07/202409:00GlobeNewswire Inc.Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private PlacementNASDAQ:HEPAHepion Pharmaceuticals Inc
21/05/202418:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HEPAHepion Pharmaceuticals Inc
15/05/202417:46Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:HEPAHepion Pharmaceuticals Inc
19/04/202417:30GlobeNewswire Inc.Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ TrialNASDAQ:HEPAHepion Pharmaceuticals Inc
16/02/202410:00GlobeNewswire Inc.Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsNASDAQ:HEPAHepion Pharmaceuticals Inc
14/02/202417:38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:HEPAHepion Pharmaceuticals Inc
03/01/202419:15GlobeNewswire Inc.Hepion Pharmaceuticals to Present at NASH-TAG 2024NASDAQ:HEPAHepion Pharmaceuticals Inc
07/12/202310:00GlobeNewswire Inc.Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesNASDAQ:HEPAHepion Pharmaceuticals Inc
28/11/202318:15GlobeNewswire Inc.Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development SummitNASDAQ:HEPAHepion Pharmaceuticals Inc
13/11/202318:05GlobeNewswire Inc.Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver DiseaseNASDAQ:HEPAHepion Pharmaceuticals Inc
10/11/202310:50GlobeNewswire Inc.Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
09/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:HEPAHepion Pharmaceuticals Inc
25/10/202309:30GlobeNewswire Inc.Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer ModelNASDAQ:HEPAHepion Pharmaceuticals Inc
29/09/202309:00GlobeNewswire Inc.Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq RulesNASDAQ:HEPAHepion Pharmaceuticals Inc
21/09/202317:05GlobeNewswire Inc.Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare ConferenceNASDAQ:HEPAHepion Pharmaceuticals Inc
21/09/202309:00GlobeNewswire Inc.New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening ProgramNASDAQ:HEPAHepion Pharmaceuticals Inc
19/09/202310:00GlobeNewswire Inc.Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver CancerNASDAQ:HEPAHepion Pharmaceuticals Inc
18/09/202309:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HEPAHepion Pharmaceuticals Inc
14/09/202309:45GlobeNewswire Inc.Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary FibrosisNASDAQ:HEPAHepion Pharmaceuticals Inc
06/09/202317:30GlobeNewswire Inc.Hepion Pharmaceuticals Announces Management ChangesNASDAQ:HEPAHepion Pharmaceuticals Inc
21/07/202317:39Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HEPAHepion Pharmaceuticals Inc
15/06/202317:45GlobeNewswire Inc.Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023NASDAQ:HEPAHepion Pharmaceuticals Inc
15/06/202309:22GlobeNewswire Inc.Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
24/05/202317:45GlobeNewswire Inc.Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical SciencesNASDAQ:HEPAHepion Pharmaceuticals Inc
22/05/202308:00GlobeNewswire Inc.Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH BiomarkersNASDAQ:HEPAHepion Pharmaceuticals Inc
19/05/202317:05GlobeNewswire Inc.Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
12/05/202317:19Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:HEPAHepion Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:HEPA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HAGA3
HAGA ON
BOV
PRIO3
PETRORIO ON
BOV
AZEV4
AZEVEDO PN
BOV
AZUL4
AZUL PN
BOV
COGN3
COGNA ON
BOV
RNEW4
RENOVA PN
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
PDGR3
PDG REALT ON
BOV
RAIZ4
Raizen S.A PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
TPIS3
TRIUNFO PART ON
BOV
GFSA3
GAFISA ON
BOV
OIBR3
OI ON
BOV
AZEV3
AZEVEDO ON
BOV
MGLU3
MAGAZINE LUIZA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados